Production (Stage)
Silence Therapeutics plc
SLN
$5.19
$0.193.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -99.44% | 1,619.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -99.44% | 1,619.15% | |||
| Cost of Revenue | -97.61% | -37.28% | |||
| Gross Profit | -99.62% | 1,196.40% | |||
| SG&A Expenses | 13.32% | -6.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.81% | -39.07% | |||
| Operating Income | -479.80% | 123.10% | |||
| Income Before Tax | -247.52% | 149.28% | |||
| Income Tax Expenses | -- | 319.84% | |||
| Earnings from Continuing Operations | -375.94% | 129.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -375.94% | 129.41% | |||
| EBIT | -479.80% | 123.10% | |||
| EBITDA | -469.59% | 123.73% | |||
| EPS Basic | -375.97% | 129.31% | |||
| Normalized Basic EPS | -247.56% | 149.11% | |||
| EPS Diluted | -375.97% | 129.31% | |||
| Normalized Diluted EPS | -247.56% | 149.11% | |||
| Average Basic Shares Outstanding | 0.00% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||